-transparent.png){kind=logo}
Piroxantrone was administered at a starting dose of 160 mg m2 given as a 1-h infusion every 3 weeks to 19 patients with histologically confirmed advanced, persistent, or recurrent squamous cell carcinoma of the cervix. All patients were required to have measurable disease and no prior chemotherapy. Eighteen women were evaluable for toxicity and response. Toxicity was modest and consisted primarily of myelosuppression with six (33%) patients experiencing grade 3 or 4 leukopenia. There were no complete (CR) or partial responses (PR) among the 18 evaluable patients. Six (33%) patients had stable disease while on treatment and 12 (67%) patients experienced progressive disease. Piroxantrone appears to have no beneficial effect in advanced or recurrent squamous cell cancer of the cervix at this dose and schedule.
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
April 1992,
Investigational new drugs,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
January 1994,
Investigational new drugs,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
December 1987,
Cancer treatment reports,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
January 1986,
Investigational new drugs,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
January 1986,
Investigational new drugs,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
July 1992,
Investigational new drugs,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
February 1983,
Cancer treatment reports,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
August 2002,
Cancer chemotherapy and pharmacology,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
July 2009,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
S Lincoln, and
J A Blessing, and
R McGehee, and
S S Lentz
September 1987,
Cancer treatment reports,
